Collagen Solutions Investor Evening

On Monday 26 February, Jamal Rushdy, CEO of Collagen Solutions gave an update to investors on the results of their study involving ChondroMimetic® and in particular the significance of the clinical data compared to current competitive procedures.

Key data highlights from the clinical study were:

  • Quantitative 3D MRI analysis in the long-term study concluded that cartilage regeneration in the treated defects had reached a level and structural quality nearly identical to native cartilage.
  • Improvement in patient clinical symptoms, including pain, function and activity level after treatment sustained over the eight-year period.
  • The ‘Knee Injury and Osteoarthritis Outcome Score’ (KOOS), a well-known and validated patient reported outcome measure, showed outcomes following the ChondroMimetic® procedure were equal to or better than KOOS scores reported in the literature for substantially more expensive two-stage cartilage repair technologies.

Jamal also summarised the key milestones expected this year for both ChondroMimetric® and the Company’s core business activities.

A copy of the presentation slides can be found here.

The Hardman & Co research note can also be found here.